TEVA B1 (Letrozole 2.5 mg)

Pill imprint TEVA B1 has been identified as Letrozole 2.5 mg.

Letrozole is used in the treatment of female infertility; breast cancer, metastatic; breast cancer; breast cancer, adjuvant and belongs to the drug classes aromatase inhibitors, hormones/antineoplastics. There is positive evidence of human fetal risk during pregnancy. Letrozole 2.5 mg is not a controlled substance under the Controlled Substance Act (CSA).

Letrozole

Imprint:

TEVA B1

Strength:

2.5 mg

Color:

Yellow

Shape:

Round

Availability:

Prescription only

Drug Class:

Aromatase inhibitors
Hormones/antineoplastics

Pregnancy Category:

D - Positive evidence of risk

CSA Schedule:

Not a controlled drug

Manufacturer:

Teva Pharmaceuticals USA Inc

National Drug Code (NDC):

00093-7620

Inactive Ingredients:

silicon dioxide
FD&C Blue No. 2
aluminum oxide
FD&C Yellow No. 5
ferric oxide yellow
lactose monohydrate
magnesium stearate
microcrystalline cellulose
polyethylene glycol
polyvinyl alcohol
sodium starch glycolate type A potato
corn starch
magnesium silicate
titanium dioxide

Other Manufacturers / Repackagers:

NDC Code	Manufacturer / Repackager
42291-0374	AvKare, Inc.

Note: Inactive ingredients may vary.

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.